Regulus Therapeutics
RGLS
#7084
Rank
โ‚น54.56 B
Marketcap
โ‚น788.09
Share price
0.00%
Change (1 day)
506.16%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.47 Billion a decrease over its 2023 earnings that were of -โ‚น2.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-10.09%
2024 -โ‚น4.47 Billion56.97%
2023 -โ‚น2.85 Billion6.51%
2022 -โ‚น2.67 Billion2.53%
2021 -โ‚น2.61 Billion93.59%
2020 -โ‚น1.35 Billion-15.41%
2019 -โ‚น1.59 Billion-64.46%
2018 -โ‚น4.48 Billion-33.26%
2017 -โ‚น6.71 Billion-13.98%
2016 -โ‚น7.79 Billion44.77%
2015 -โ‚น5.39 Billion-1.63%
2014 -โ‚น5.48 Billion203.6%
2013 -โ‚น1.81 Billion8.65%
2012 -โ‚น1.66 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น739.65 B-16,247.25%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น156.74 B-3,521.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น926.87 B-20,334.46%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.416 T-31,017.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น966.90 B-21,208.18%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น10.53 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น11.37 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น83.99 B-1,933.62%๐Ÿ‡บ๐Ÿ‡ธ USA